Adam C. Olson
Advanced in Fibrosarcoma

Dr. Adam C. Olson

Radiation Oncology
UPMC Hillman Cancer Center
300 Halket Street, 
Pittsburgh, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Advanced in Fibrosarcoma
UPMC Hillman Cancer Center
300 Halket Street, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Adam Olson, MD, is a radiation oncologist in the UPMC Department of Radiation Oncology. He is the medical director of Radiation Oncology at UPMC Children's Hospital of Pittsburgh. At UPMC Shadyside, his clinical practice focuses on the management of genitourinary cancers and soft tissue sarcomas. He is an expert in the use of stereotactic body radiation therapy for prostate cancer and metastatic disease. He is an active clinical researcher and has published extensively on the use of radiation therapy for prostate cancer and pediatric cancers.

Dr. Olson is rated as an Advanced provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Adult Soft Tissue Sarcoma, and Merkel Cell Carcinoma.

His clinical research consists of co-authoring 39 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in PA
Board Certifications
American Board Of Radiology
Hospital Affiliations
Magee Womens Hospital Of Upmc Health System
Upmc Presbyterian Shadyside
Upmc Altoona
Upmc Passavant
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

UPMC Hillman Cancer Center
300 Halket Street, Pittsburgh, PA 15213
Other Locations
Mary Hillman Jennings Radiation Oncology Center
5230 Centre Avenue, Pittsburgh, PA 15232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Other, Radiation
Study Drug: Cabozantinib S-malate
Study Phase: Phase 2
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Radiation, Drug
Study Drugs: Enzalutamide, Bicalutamide, GnRH analog
Study Phase: Phase 2
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Olaparib, Radium-223
Study Phase: Phase 1/Phase 2
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy in High Risk Prostate Cancer (With Initial Phase I)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: Gonadotrophin releasing hormone, Niraparib
Study Phase: Phase 1/Phase 2
Hepatocyte Transplantation for Phenylketonuria
Hepatocyte Transplantation for Phenylketonuria
Enrollment Status: Terminated
Publish Date: August 16, 2023
Intervention Type: Drug, Other, Procedure, Diagnostic test, Radiation, Behavioral
Study Drug: Immunosuppression
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

39 Total Publications

ALARA in Antimicrobial Stewardship: Adapting Radiation Safety Principles to Address Antibiotic Overuse.
ALARA in Antimicrobial Stewardship: Adapting Radiation Safety Principles to Address Antibiotic Overuse.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: September 26, 2025
Similar Doctors
Experienced in Fibrosarcoma
Dr. Jondavid Pollock
Radiation Oncology
Experienced in Fibrosarcoma
Dr. Jondavid Pollock
Radiation Oncology

Wheeling Hospital Inc

1 Medical Park, 
Wheeling, WV 
 (46.3 miles away)
304-243-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jondavid Pollock is a Radiation Oncologist in Wheeling, West Virginia. Dr. Pollock is rated as a Distinguished provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Laryngeal Cancer, and Pleuropulmonary Blastoma. Dr. Pollock is currently accepting new patients.

Experienced in Fibrosarcoma
Dr. Tamara Z. Vern-Gross
Radiation Oncology | Pediatrics
Experienced in Fibrosarcoma
Dr. Tamara Z. Vern-Gross
Radiation Oncology | Pediatrics

Mercy Health Physicians Youngstown Specialty Care LLC

1044 Belmont Ave, 
Youngstown, OH 
 (59.3 miles away)
330-480-3655
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Tamara Vern-Gross is a Radiation Oncologist and a Pediatrics provider in Youngstown, Ohio. Dr. Vern-Gross is rated as an Advanced provider by MediFind in the treatment of Fibrosarcoma. Her top areas of expertise are Breast Cancer, Angiosarcoma, Rhabdomyosarcoma, and Rhabdoid Tumor. Dr. Vern-Gross is currently accepting new patients.

Experienced in Fibrosarcoma
Dr. Stephen M. Karlovits
Radiation Oncology | Radiology
Experienced in Fibrosarcoma
Dr. Stephen M. Karlovits
Radiation Oncology | Radiology

Allegheny Clinic

1 Nolte Dr, 
Kittanning, PA 
 (33.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Karlovits is a Radiation Oncologist and a Radiologist in Kittanning, Pennsylvania. Dr. Karlovits is rated as an Advanced provider by MediFind in the treatment of Fibrosarcoma. His top areas of expertise are Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, Breast Cancer, and Metastatic Brain Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Olson's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile